Related Experiment Video

Updated: Feb 19, 2026

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

1.5K

Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus

Amanda Trang1, David Aguilar2

  • 1Cardiovascular Division, Baylor College of Medicine, 6620 Main Street, Houston, TX, 77030, USA.

Current Heart Failure Reports
|November 3, 2017
PubMed

Insights

Sodium-glucose cotransporter 2 (SGLT2) inhibitors show promise in improving outcomes for diabetic patients with heart failure. These agents offer a novel approach beyond glycemic control for managing cardiorenal risk.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetes and heart failure frequently coexist, worsening patient prognosis.
  • Poor glycemic control is associated with adverse heart failure outcomes.
  • Some glucose-lowering agents may negatively impact heart failure.

Purpose of the Study:

  • To explore mechanisms linking diabetes and heart failure for potential therapeutic targets.
  • To review the impact of current glucose-lowering drugs on heart failure outcomes.

Main Methods:

  • Review of contemporary glucose-lowering agents.
  • Analysis of clinical trial data on heart failure outcomes in diabetic patients.
  • Exploration of mechanistic pathways.

Main Results:

  • Sodium-glucose cotransporter 2 (SGLT2) inhibitors demonstrate improved cardiovascular mortality and heart failure outcomes in diabetic individuals.
  • SGLT2 inhibitors show efficacy in patients both with and without established heart failure.
  • Targeting glycemic control alone has not been sufficient for improving heart failure outcomes.

Conclusions:

  • SGLT2 inhibitors represent a promising therapeutic class for diabetic patients with heart failure.
  • These agents target multiple mechanisms relevant to both diabetes and heart failure.
  • SGLT2 inhibitors may play a role in primary heart failure prevention and treatment in diabetic populations.
Abstract

Keywords:
DiabetesHeart failureSodium-glucose cotransporter 2

More Related Videos

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

675

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
381
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.2K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.0K
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
417
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K